These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38598026)

  • 21. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island.
    Collins AB; Macon EC; Langdon K; Joseph R; Thomas A; Dogon C; Beckwith CG
    J Urban Health; 2023 Oct; 100(5):1062-1073. PubMed ID: 37563518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States.
    Philbin MM; Parish C; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
    AIDS Behav; 2021 Mar; 25(3):667-678. PubMed ID: 32910351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda-A qualitative study.
    Ross J; Ingabire C; Umwiza F; Gasana J; Munyaneza A; Murenzi G; Nsanzimana S; Remera E; Akiyama MJ; Anastos KM; Adedimeji A
    PLoS One; 2021; 16(5):e0251645. PubMed ID: 33984044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives.
    Koester KA; Colasanti JA; McNulty MC; Dance K; Erguera XA; Tsuzuki MD; Johnson MO; Sauceda JA; Montgomery E; Schneider J; Christopoulos KA
    Implement Sci Commun; 2023 Oct; 4(1):128. PubMed ID: 37858272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences.
    Carillon S; Gallardo L; Linard F; Chakvetadze C; Viard JP; Cros A; Molina JM; Slama L
    AIDS Care; 2020 May; 32(sup2):155-161. PubMed ID: 32189506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and/or housing instability.
    Fletcher L; Burrowes SAB; Khan GK; Sabin L; Johnson S; Kimmel SD; Ruiz-Mercado G; Pierre C; Drainoni ML
    Harm Reduct J; 2023 Jan; 20(1):4. PubMed ID: 36627679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.
    Okafor CN; Eaton L; Watson R
    AIDS Behav; 2024 Jun; 28(6):2166-2174. PubMed ID: 38526639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.
    Haser GC; Balter L; Gurley S; Thomas M; Murphy T; Sumitani J; Leue EP; Hollman A; Karneh M; Wray L; Washington M; Corbin-Johnson D; Condra A; Niles-Carnes L; Smith BL; Armstrong WS; Kalokhe AS; Colasanti JA; Collins LF
    AIDS Res Hum Retroviruses; 2024 Jul; ():. PubMed ID: 38959116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV.
    Gandhi M; Hickey M; Imbert E; Grochowski J; Mayorga-Munoz F; Szumowski JD; Oskarsson J; Shiels M; Sauceda J; Salazar J; Dilworth S; Nguyen JQ; Glidden DV; Havlir DV; Christopoulos KA
    Ann Intern Med; 2023 Jul; 176(7):969-974. PubMed ID: 37399555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.
    Simoni JM; Tapia K; Lee SJ; Graham SM; Beima-Sofie K; Mohamed ZH; Christodoulou J; Ho R; Collier AC
    AIDS Behav; 2020 Apr; 24(4):1226-1236. PubMed ID: 31655915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.
    Kanazawa JT; Saberi P; Sauceda JA; Dubé K
    AIDS Res Hum Retroviruses; 2021 Feb; 37(2):75-88. PubMed ID: 33176429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical race theory as a tool for understanding poor engagement along the HIV care continuum among African American/Black and Hispanic persons living with HIV in the United States: a qualitative exploration.
    Freeman R; Gwadz MV; Silverman E; Kutnick A; Leonard NR; Ritchie AS; Reed J; Martinez BY
    Int J Equity Health; 2017 Mar; 16(1):54. PubMed ID: 28340589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retained in HIV Care But Not on Antiretroviral Treatment: A Qualitative Patient-Provider Dyadic Study.
    Christopoulos KA; Olender S; Lopez AM; Lekas HM; Jaiswal J; Mellman W; Geng E; Koester KA
    PLoS Med; 2015 Aug; 12(8):e1001863. PubMed ID: 26263532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
    Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
    J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving HIV Care Engagement in the South from the Patient and Provider Perspective: The Role of Stigma, Social Support, and Shared Decision-Making.
    Taylor BS; Fornos L; Tarbutton J; Muñoz J; Saber JA; Bullock D; Villarreal R; Nijhawan AE
    AIDS Patient Care STDS; 2018 Sep; 32(9):368-378. PubMed ID: 30179530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How food insecurity contributes to poor HIV health outcomes: Qualitative evidence from the San Francisco Bay Area.
    Whittle HJ; Palar K; Seligman HK; Napoles T; Frongillo EA; Weiser SD
    Soc Sci Med; 2016 Dec; 170():228-236. PubMed ID: 27771206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study.
    Rutstein SE; Sibley AL; Huffstetler HE; Nguyen TTD; Tran HV; Le Minh G; Sripaipan T; Nguyen M; Miller WC; Eron JJ; Gay CL; Go VF
    Lancet Reg Health West Pac; 2023 Feb; 31():100603. PubMed ID: 36879789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.